A company repositioning drugs used to treat high blood pressure for use in improving chemotherapy has secured $3 million from investors to carry its lead candidate through Phase 1 trials. Tau Therapeutics is repurposing the calcium channel blocker mibefradil for use alongside chemotherapy in patients with solid tumor cancers, starting with brain cancer. After having its investigational new drug application accepted in February, the University of Virginia spinout has just closed a $3 million round of equity financing to support a Phase 1b study in collaboration with the National Cancer Ins...